NSE · NECLIFE
Nectar Lifesciences Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹0 Cr with net profit ₹-13 Cr — a -2986.36% net margin, versus -3152.42% the period before.
Shareholding
As of 2026-09-30
- Promoter51.84%
- Public43.76%
- FII0.5%
- DII3.9%
72,334 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.41× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #64 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,276 Cr | 36.26 | 5 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,26,433 Cr | 94.35 | 20.82 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,19,491 Cr | 26.29 | 4.29 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,14,683 Cr | 40.96 | 2.95 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,13,991 Cr | 36.71 | 3.22 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,04,913 Cr | 44.96 | 5.97 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,03,568 Cr | 25.52 | 2.62 | 10.13% | 10.88% |
| Lupin Limited | ₹90,914 Cr | 16.14 | 3.78 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹73,096 Cr | 23.42 | 6.53 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹63,334 Cr | 27.79 | 4.56 | 16.66% | 14.31% |
| Nectar Lifesciences Ltd.(this company) | ₹195 Cr | — | 0.34 | -9.85% | -2450600% |
AI analysis
AI-generated · google/gemini-2.5-flashNectar Lifesciences Ltd. is listed on the Indian markets with a market capitalization of Rs 210 Cr. The company reported revenue of Rs 1674.97 Cr and a negative profit margin of -4762.44%. The debt-to-equity ratio is 0.6.
Positives
- +Promoter holding is 51.8408% as of June 30, 2026, indicating significant insider ownership.
Negatives
- −The company reported a negative profit margin of -4762.44%.
- −Revenue growth for Mar 2025 was negative at -0.8%.
- −Return on equity (ROE) is negative at -9.85% and return on capital employed (ROCE) is negative at -8.7498%.
- −The company's EPS for Mar 2025 was negative at -5.07.
- −The company is currently under ESM Stage 1 surveillance.
Financial Performance
Nectar Lifesciences Ltd. reported annual revenue of Rs 1674.97 Cr for Mar 2025, which reflects a revenue growth of -0.8%. The company's net profit for Mar 2025 was -113.681 Cr, resulting in an EPS of -5.07. More recently, for Mar 2026, the company recorded a revenue of Rs 1.29 Cr and a net profit of -67.92 Cr.
Profitability & Returns
The company's profitability metrics indicate a challenging financial period, with a negative profit margin of -4762.44%. Return on equity (ROE) stands at -9.85% and return on capital employed (ROCE) is -8.7498%.
Balance Sheet
Nectar Lifesciences Ltd. has a book value of Rs 29.97. The company's debt-to-equity ratio is 0.6, indicating its reliance on debt financing relative to equity. The EPS for Mar 2025 was -5.07, and for Mar 2026, the company reported a net profit of -67.92 Cr on a revenue of Rs 1.29 Cr.
Ownership & Pledges
Over the years, promoter pledge percentages have varied, reaching 55.85% in December 2018 and March 2017.
Regulatory & Surveillance
Nectar Lifesciences Ltd. is currently under ESM (Enhanced Surveillance Measure) Stage 1, indicating increased monitoring by regulatory authorities due to certain identified parameters.
Data as of — price: 2026-11-07 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.